Coeptis Therapeutics expanded license agreement with University of Pittsburgh

Coeptis Therapeutics announced that it has expanded its exclusive license agreement with the University of Pittsburgh to include autoimmune indications as part of its ongoing development of SNAP-CAR T and SNAP-CAR NK. This amended agreement builds upon the original exclusive license agreement with the University of Pittsburgh for SNAP-CAR T Cells, a “universal” CAR T technology platform designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, and a recent amendment to the agreement for SNAP-CAR NK, an allogeneic natural killer cell therapy platform. Research published in the peer-reviewed journal Nature Communications demonstrated the ability of SNAP-CAR to provide a powerful adaptor strategy for fully programmable targeting of engineered cells to multiple antigens, including CD19. Based on these findings, Coeptis Therapeutics plans to expand the development of the SNAP-CAR platform to target the multibillion-dollar autoimmune disease market in addition to hematologic and solid tumors. “We remain committed to developing these remarkable technologies as treatments for various indications across oncology where there is immense unmet need, however we also recognize the enormous potential for these platform technologies to address and possibly revolutionize the treatment landscape of autoimmune diseases,” said Dave Mehalick, President and CEO of Coeptis Therapeutics. “Our SNAP-CAR technologies have the potential to position us at the forefront of next-generation autoimmune directed therapies targeting multiple antigens through combinatorial use of different adaptors.”